Technical Analysis for RYTM - Rhythm Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 27.33 1.56% 0.42
RYTM closed up 1.56 percent on Wednesday, January 17, 2018, on 83 percent of normal volume. It ran into resistance at its 50 day moving average.
0 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Flat Down
See historical RYTM trend table...

Date Alert Name Type % Chg
Jan 17 50 DMA Resistance Bearish 0.00%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 16 Fell Below 50 DMA Bearish 1.56%
Jan 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.56%
Jan 16 Outside Day Range Expansion 1.56%
Jan 16 Wide Bands Range Expansion 1.56%
Jan 12 Crossed Above 50 DMA Bullish -0.26%
Jan 12 Inside Day Range Contraction -0.26%
Jan 12 Wide Bands Range Expansion -0.26%

Older signals for RYTM ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.
Is RYTM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.81
52 Week Low 21.38
Average Volume 146,148
200-Day Moving Average 0.0
50-Day Moving Average 27.3946
20-Day Moving Average 28.2875
10-Day Moving Average 27.469
Average True Range 1.6367
ADX 16.12
+DI 16.35
-DI 19.06
Chandelier Exit (Long, 3 ATRs ) 26.7199
Chandelier Exit (Short, 3 ATRs ) 30.0801
Upper Bollinger Band 30.5843
Lower Bollinger Band 25.9907
Percent B (%b) 0.29
BandWidth 16.238975
MACD Line -0.2304
MACD Signal Line -0.0115
MACD Histogram -0.2189
Fundamentals Value
Market Cap 712.61 Million
Num Shares 26.1 Million
EPS -3.13
Price-to-Earnings (P/E) Ratio -8.73
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.77
Resistance 3 (R3) 29.79 28.99 29.36
Resistance 2 (R2) 28.99 28.37 28.98 29.23
Resistance 1 (R1) 28.16 27.99 28.58 28.14 29.09
Pivot Point 27.37 27.37 27.57 27.36 27.37
Support 1 (S1) 26.54 26.74 26.95 26.52 25.57
Support 2 (S2) 25.74 26.36 25.73 25.43
Support 3 (S3) 24.91 25.74 25.30
Support 4 (S4) 24.89